Development of a Genome-Scale Metabolic Model and Phenome Analysis of the Probiotic Escherichia coli Strain Nissle 1917
- PMID: 33672760
- PMCID: PMC7924626
- DOI: 10.3390/ijms22042122
Development of a Genome-Scale Metabolic Model and Phenome Analysis of the Probiotic Escherichia coli Strain Nissle 1917
Abstract
Escherichia coli Nissle 1917 (EcN) is an intestinal probiotic that is effective for the treatment of intestinal disorders, such as inflammatory bowel disease and ulcerative colitis. EcN is a representative Gram-negative probiotic in biomedical research and is an intensively studied probiotic. However, to date, its genome-wide metabolic network model has not been developed. Here, we developed a comprehensive and highly curated EcN metabolic model, referred to as iDK1463, based on genome comparison and phenome analysis. The model was improved and validated by comparing the simulation results with experimental results from phenotype microarray tests. iDK1463 comprises 1463 genes, 1313 unique metabolites, and 2984 metabolic reactions. Phenome data of EcN were compared with those of Escherichia coli intestinal commensal K-12 MG1655. iDK1463 was simulated to identify the genetic determinants responsible for the observed phenotypic differences between EcN and K-12. Further, the model was simulated for gene essentiality analysis and utilization of nutrient sources under anaerobic growth conditions. These analyses provided insights into the metabolic mechanisms by which EcN colonizes and persists in the gut. iDK1463 will contribute to the system-level understanding of the functional capacity of gut microbes and their interactions with microbiota and human hosts, as well as the development of live microbial therapeutics.
Keywords: Escherichia coli Nissle 1917; flux balance analysis; metabolic network model; phenome analysis; probiotics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
High-quality genome-scale metabolic network reconstruction of probiotic bacterium Escherichia coli Nissle 1917.BMC Bioinformatics. 2022 Dec 30;23(1):566. doi: 10.1186/s12859-022-05108-9. BMC Bioinformatics. 2022. PMID: 36585633 Free PMC article.
-
Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability.Metab Eng. 2024 Nov;86:157-171. doi: 10.1016/j.ymben.2024.10.002. Epub 2024 Oct 9. Metab Eng. 2024. PMID: 39389255
-
Effect of antibiotic, probiotic, and human rotavirus infection on colonisation dynamics of defined commensal microbiota in a gnotobiotic pig model.Benef Microbes. 2018 Jan 29;9(1):71-86. doi: 10.3920/BM2016.0225. Epub 2017 Oct 12. Benef Microbes. 2018. PMID: 29022385
-
Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917.Crit Rev Microbiol. 2023 Sep;49(5):611-627. doi: 10.1080/1040841X.2022.2109405. Epub 2022 Aug 10. Crit Rev Microbiol. 2023. PMID: 35947523 Review.
-
[The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].Postepy Hig Med Dosw (Online). 2014 Nov 6;68:1251-6. doi: 10.5604/17322693.1127882. Postepy Hig Med Dosw (Online). 2014. PMID: 25380207 Review. Polish.
Cited by
-
Synthetic biology design principles enable efficient bioproduction of Heparosan with low molecular weight and low polydispersion index for the biomedical industry.Synth Biol (Oxf). 2025 Apr 29;10(1):ysaf006. doi: 10.1093/synbio/ysaf006. eCollection 2025. Synth Biol (Oxf). 2025. PMID: 40396182 Free PMC article.
-
Integration of metabolomics and other omics: from microbes to microbiome.Appl Microbiol Biotechnol. 2024 Dec 19;108(1):538. doi: 10.1007/s00253-024-13384-z. Appl Microbiol Biotechnol. 2024. PMID: 39702677 Free PMC article. Review.
-
Role of adherent invasive Escherichia coli in pathogenesis of inflammatory bowel disease.World J Clin Cases. 2022 Nov 16;10(32):11671-11689. doi: 10.12998/wjcc.v10.i32.11671. World J Clin Cases. 2022. PMID: 36405271 Free PMC article. Review.
-
Antibacterial MccM as the Major Microcin in Escherichia coli Nissle 1917 against Pathogenic Enterobacteria.Int J Mol Sci. 2023 Jul 20;24(14):11688. doi: 10.3390/ijms241411688. Int J Mol Sci. 2023. PMID: 37511446 Free PMC article.
-
High-quality genome-scale metabolic network reconstruction of probiotic bacterium Escherichia coli Nissle 1917.BMC Bioinformatics. 2022 Dec 30;23(1):566. doi: 10.1186/s12859-022-05108-9. BMC Bioinformatics. 2022. PMID: 36585633 Free PMC article.
References
-
- Choi H.J., Ahn J.H., Park S.H., Do K.H., Kim J., Moon Y. Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: Therapeutic implication using recombinant probiotics. Infect. Immun. 2012;80:1079–1087. doi: 10.1128/IAI.05820-11. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases